glp-1 receptor agonist pancreatitis risk meta-analysis Safety of agonists in type 1 diabetes: a systematic review and Comparative effectiveness of GLP-1 receptor

Guidelines suggest the additional use of DPP-4 inhibitors after metformin failure in patients that do not require antidiabetic therapy with proven cardiovascular benefit

These clinical trials aim to show a reduction in insulin resistance and improved glycemic management when GLP-1s are used in addition to insulin

As outlined earlier, cardiometabolic diseases or risk factors such as type 2 diabetes (Nichols et al., 2004), obesity (Powell-Wiley et al., 2021) and hypertension (Oh and Cho, 2020) are major predictors for HF

Ornelas C, Caiado J, Lopes A, Pereira Dos Santos MC, Pereira BM

Nearly half of participants in the 6 mg group (49.5%) achieved at least 15% weight reduction , compared to just 2% on placebo

If you're interested in working with our clinic, you can click the link HERE to schedule an appointment